Genom & Company’s 'trick' opened an exit path for venture capital investors

▤ Summary

Genom & Company’s stock swap structure has given its investors a viable exit path after their capital was tied up in a failed subsidiary plan. The company issued convertible bonds and later allowed investors to convert and sell shares as the stock price rose above the conversion price. DSC Investment and Paratus Investment have already realized gains by converting and selling shares. The move also helped Genom & Company clean up its balance sheet and unwind a stalled microbiome CDMO expansion in the U.S.

▦ Linked Companies